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Abstract
It has been estimated that up to half of circulating Factor XIIIa (FXIIIa) is stored in platelets. The 
release of FXIIIa from platelets upon stimulation with ADP in patients with coronary artery 
disease treated with dual antiplatelet therapy has not been previously examined. Samples from 96 
patients with established coronary artery disease treated with aspirin and clopidogrel were 
examined. Platelet aggregation was performed by light transmittance aggregometry (LTA) in 
platelet rich plasma (PRP) with platelet poor plasma (PPP) as reference and ADP 5μM as agonist. 
Kaolin activated TEG was performed in citrate PPP. PRP after aggregation was centrifuged and 
plasma supernatant (PSN) collected. FXIIIa was measured in PPP and PSN.
Platelet aggregation after stimulation with ADP 5μM resulted in 24% additional FXIIIa release in 
PSN as compared to PPP (99.3 ± 27 vs. 80.3 ± 24 %, p<0.0001). FXIIIa concentration in PSN 
correlated with maximal plasma clot strength (TEG-G) (r=0.48, p<0.0001), but not in PPP 
(r=0.15, p=0.14). Increasing quartiles of platelet derived FXIIIa were associated with 
incrementally higher TEG-G (p=0.012). FXIIIa release was similar between clopidogrel 
responders and non-responders (p=0.18). In summary, platelets treated with aspirin and 
clopidogrel release a significant amount of FXIIIa upon aggregation by ADP. Platelet derived 
FXIIIa may contribute to differences in plasma TEG-G, and thus in part provide a mechanistic 
explanation for high clot strength observed as a consequence of platelet activation. Variability in 
clopidogrel response does not significantly influence FXIIIa release from platelets.
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Introduction
Factor XIII (FXIII) is a transglutaminase consisting of 2 separate isoforms assembled into a 
tetramer of 2 FXIIIa active isomers and 2 FXIIIb isomers that bind the active FXIIIa [1]. 
Cleavage by thrombin frees FXIIIa with its primary role being cross stabilization of soluble 
fibrin strands [1,2]. Congenital FXIII deficiency leads to a bleeding diathesis, that if 
untreated can be fatal early in life [3]. Beyond its purpose of fibrin stabilization, other roles 
of FXIII have been identified in angiogenesis and wound healing [4,5].
FXIIIa is predominantly synthesized in cells of bone marrow origin and bound by the excess 
FXIIIb in plasma as an inactive tetramer (A2B2) [6]. In megacaryocytes, platelets, and 
leukocytes it is present in a cellular form (cFXIII) in a dimer structure of FXIIIa (A2) [6]. 
Megacaryocytes synthesize the majority of FXIIIa and package FXIIIa as well as encoding 
mRNA into platelets [7]. FXIIIa is highly abundant in platelets, and has been demonstrated 
predominantly in the cytoplasm [8,9]. It has been estimated that up to 50% of total FXIIIa is 
stored in platelets with a lesser amount found in macrophages/monocytes [1]. The role of 
FXIIIa derived from platelets in local dynamics of fibrin stabilization in platelet rich 
thrombus, such as found in high shear conditions of arterial thrombosis remains uncertain. 
Recently Kasahara et al. reported that platelet-dependent clot retraction requires factor XIII 
(FXIII), which covalently associates fibrin polymers with protein located within the platelet 
plasma membrane at lipid rafts [10]. High clot strength in whole blood assays measured by 
thrombelastography (TEG) appears to be a risk factor for increased risk of coronary 
thrombosis after coronary stenting and coronary artery bypass grafting (CABG) [11,12]. 
Antiplatelet therapy may affect local thrombus generation dynamics and fibrin stabilization 
by inhibiting FXIIIa activity on the surface of platelets or preventing release of FXIIIa into 
plasma [13]. FXIIIa release from platelets during platelet aggregation in patients with 
coronary artery disease treated with dual antiplatelet therapy has not been previously 
quantified.
We hypothesized that despite dual antiplatelet therapy with aspirin and clopidogrel, FXIII is 
being released from platelets and thus may contribute to fibrin stabilization in vivo in 
patients with coronary artery disease treated with standard antiplatelet therapy.
Methods
Patients
The study protocol was approved by the Indiana University institutional review board for 
research. Written informed consent was obtained from all subjects. Subjects with established 
coronary artery disease who were taking clopidogrel 75 mg and aspirin 81-325 mg daily for 
at least 14 days prior to enrollment were eligible for recruitment in the study. Subjects were 
excluded if they had a history of medication noncompliance, drug or alcohol abuse, bleeding 
disorder, platelet count less than 150,000/mm3, myelodysplastic or myeloproliferative 
disorders, if they were taking dipyridamole or warfarin, if they had chronic liver disease 
(hepatic transaminases greater than or equal to 3×ULN), or renal disease (serum creatinine 
greater than 2.0 mg/dl). Because the recruited subjects were requiring dual antiplatelet 
pharmacotherapy, baseline predrug platelet aggregation studies were not performed.
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Blood samples
Blood was obtained from an antecubital or forearm vein using a 21 gauge needle with 
vacutainer collection tubing. The first 4 ml of blood drawn was discarded to avoid 
spontaneous platelet activation. Blood was collected in 3.2 % sodium citrate tubes to fill 
volume and a single Greiner partial fill (1.8 ml) blood collection tube containing 3.2% 
sodium citrate (Greiner Bio-One, NA, Inc., Monroe, NC, USA). VerifyNow was completed 
within 30 minutes after blood draw but no sooner than 10 minutes according to testing 
instructions, and LTA was completed within 2 hours of the blood draw.
Platelet aggregation studies
Ex vivo platelet function was assessed by light transmittance aggregometry (LTA) at 37°C 
with an Optical Lumi-Aggregometer (Model 700 with AggroLink 8 software, Chrono-Log 
Corporation, Havertown, PA, USA). Platelet rich plasma (PRP) and platelet poor plasma 
(PPP) were obtained by differential centrifugation as previously described [12,14,15]. In 
short, PRP was obtained from citrate blood after centrifugation at 180 g for 5 minutes. After 
recovering the PRP, the blood samples were subjected to further centrifugation at 2000 g for 
15 minutes to recover platelet poor plasma (PPP). The resulting PRP and PPP were kept at 
room temperature for use within one hour. Platelet aggregation in PRP was induced with 
adenosine diphosphate (ADP) at 5μmol/L. The resultant PRP after platelet aggregation was 
collected and centrifuged at 2000 × g for 15 minutes to separate the plasma from the platelet 
pellet and collect the platelet supernatant plasma (PSN). Platelet count was measured (ACT 
10, Beckman Coulter Inc., Brea, CA, USA) in whole blood and PRP. PPP and PSN were 
stored frozen at -80° Celsius.
VerifyNow™(VN) P2Y12 (Accumetrics Inc., San Diego, CA, USA) point-of-care assay was 
used to assess platelet inhibition in whole blood in subjects during maintenance clopidogrel 
dosing according to the manufacturer's instructions. Clopidogrel non-response was defined 
as PRU>208 [16].
ELISA
Factor XIIIa concentration (FXIII-subunit A) was measured in both PPP and PSN from PRP 
previously aggregated with 5μM ADP stimulation by enzyme linked immunoassay 
according to the manufacturer's instructions (Aniara, West Chester, OH, USA). In the assay 
the FXIIIa concentration is expressed as (%), standardized to a normal human citrated 
plasma pool. The average normal concentration of FXIII tetramer in plasma is ∼25 μg/ml 
according to the manufacturer of the assay.
Thrombelastography
Thrombelastography was performed in citrate PPP according to the manufacturer's 
instructions (Haemoscope, USA) [17]. Plasma was mixed with kaolin, inverted five times, 
and then loaded in a cup containing 20μl of CaCl2. Thrombelastography was stopped after 
maximal fibrin clot strength was recorded. Time to fibrin formation (R), angle constant (K) , 
angle (α) and maximal clot strength (MA, mm and G, dyn/cm2) were recorded. TEG – G 
was calculated from TEG – MA by use of the following formula: G = (5000*MA)/(100-
MA)
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Statistical Analysis
Analysis was performed with SPSS software (version 21, IBM, USA). Statistical 
significance was defined as p < 0.05. Tests were conducted 2-sided and values are 
represented as mean ± SD unless otherwise specified. Categorical variables were compared 
using the χ2 test. Normal distribution of continuous data was assessed by the Kolmogorov–
Smirnov test. Two-sided Student's t-test was used to compare normally distributed 
continuous data between two groups and by analysis of variance for multiple groups with 
Bonferroni correction for pairwise comparisons. Pearson's correlation coefficient was used 
to calculate correlation between measures of platelet reactivity, TEG, and FXIIIa.
Results
Clinical variables of subjects enrolled in the study are summarized in Table 1. Factor XIIIa 
concentration in PPP was within the expected range. FXIIIa concentration in plasma 
supernatant (PSN) after stimulation of PRP with ADP 5μM was 24% higher than in PPP 
(99.3 ± 27 vs. 80.3 ± 24 %, p<0.0001) (Fig 1). Mean platelet count in whole blood was 264 
± 73 (*103/μl) and 375 ± 117 (*103/μl) in PRP. The amount of platelet derived FXIIIa (Δ 
FXIIIa) was calculated by subtracting FXIIIa PPP from FXIIIa PSN concentrations. Mean Δ 
FXIIIa was 19 ± 29 %. The ratio of FXIIIa released in relation to platelet count was 
calculated by dividing Δ FXIIIa by platelet count in PRP and was 0.056 ± 0.09 %*μl/103 
platelets. Maximal platelet aggregation by light transmittance aggregometry (ADP5 μM) 
was 32.2 ± 12 % and 206 ± 77 by VerifyNow P2Y12 assay. Mean TEG measures are listed 
in Table 2.
Pearson's correlation analysis of platelet aggregation, thrombelastography, and FXIIIa 
concentrations was performed and is shown in Table 3. There was a strong correlation 
between FXIIIa concentrations in PPP and PSN (Table 3, Fig 2.). Maximal platelet 
aggregation by LTA correlated strongly with VN P2Y12 PRU. Maximal plasma clot 
strength (TEG-G) significantly correlated with FXIIIa PSN and Δ FXIIIa, but not FXIII PPP 
(Table 3, Fig 2). There was no significant correlation between maximal platelet aggregation 
by LTA or VN P2Y12 and FXIIIa concentrations. When subjects were divided into 
clopidogrel responders and non-responders based on VN P2Y12 PRU, there was no 
significant difference in FXIIIa concentrations or ratio of Δ FXIII/platelet between 
responders and non-responders (Fig 3). Similarly, when grouped according to LTA (<42% 
MPA), there was no significant difference in Δ FXIIIa between responders and non-
responders (20.7 ± 30 vs. 12.8 ± 24 %; p=0.27). Increasing quartiles of TEG-G were 
associated with increasing concentrations of FXIIIa in PPP and PSN (Fig 3). When analyzed 
in quartiles of platelet derived FXIIIa (Δ FXIIIa), TEG-G was highest in the highest quartile 
of Δ FXIIIa (Fig 3).
Discussion
FXIIIa is essential in cross linking of soluble fibrin strands and the generation of stable 
fibrin clot. It has been estimated that up to half of circulating FXIIIa is stored in platelets, 
with a smaller pool found in monocytes, while the remainder is present in plasma and bound 
to FXIIIB [18]. It has not been previously established whether FXIIIa found in platelets is 
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released upon platelet activation and whether it is influenced by the degree of platelet 
aggregation in patients treated with dual antiplatelet therapy. We demonstrate a mean 24% 
increase in FXIIIa plasma concentration after aggregation and activation of platelets with 
ADP. Variability of platelet inhibition was not significantly associated with differences in 
FXIIIa release from platelets. In contrast, maximal clot strength by TEG correlated strongly 
with FXIIIa levels after platelet aggregation. TEG is a sensitive method to detect functional 
deficiency in FXIIIa activity [19]. Since FXIIIa is necessary for fibrin cross linking, it is 
possible that platelet derived FXIIIa contributes to the higher clot strength observed in 
individuals with higher levels of FXIIIa release. Maximal whole blood clot strength has 
been associated with increased risk for recurrent thrombotic events after coronary stenting 
and after coronary artery bypass grafting [11,20]. Thus, variability in platelet derived FXIIIa 
may contribute to differences in prothrombotic phenotypes and risk of recurrent ischemic 
events. We have previously shown that thrombin induced whole blood TEG-G is 
predominantly influenced by platelet count, whereas plasma fibrin TEG-G is higher in 
clopidogrel responders as compared to non-responders [21]. Plasma TEG-G in our study 
correlated weakly with platelet count, similar to the extent previously published [21]. We 
have previously demonstrated that increased c-reactive protein in patients with coronary 
artery disease is associated with increased plasma TEG-G [17]. Chronic inflammation is 
often associated with mild thrombocytosis, and could thus be a possible explanation for this 
correlation.
Arguably, FXIIIa deposited locally by aggregating platelets at sites of developing platelet-
fibrin thrombus, could be pivotal in accelerating thrombus stabilization under high shear 
conditions. FXIIIa has been demonstrated on the surface of activated platelets and has been 
shown to enhance platelet adhesion under flow conditions [13,22]. Alternatively, subjects 
with increased levels of platelet derived FXIIIa may concomitantly deposit other coagulation 
factors that could in part influence maximal clot formation phenotype, such as Factor V and 
Factor VII which are also found in platelet granules [9]. While the exact mechanisms of 
FXIIIa release from cells have not been elucidated, data from Cordell at al. suggest a novel 
subcellular tracking mechanism of FXIIIa in monocytes and macrophages [23]. Platelet 
derived microparticles have been shown to contain cFXIIIa and this may be a mechanism of 
release of platelet FXIIIa into plasma upon platelet activation [24].
We could not find an association between clopidogrel response status and FXIIIa release in 
our study population. While maximal platelet aggregation is blunted in clopidogrel 
responders, platelet activation and granule secretion nevertheless occurs, and may be 
sufficient to overcome the inhibitory effects of clopidogrel [25]. ADP was chosen as agonist, 
since ADP induced on treatment aggregation is a strong predictor of recurrent coronary 
thrombosis after coronary stenting, and correlates strongly with P2Y12 receptor inhibition. 
While P2Y12 receptor activation was in part inhibited by clopidogrel, P2Y1 receptor 
activation also occurred when PRP was stimulated by ADP in our study. P2Y1 activation 
triggers mobilization of calcium from internal platelet stores, which results in platelet shape 
change and weak, transient aggregation in response to ADP [26]. It may therefore be 
possible that the release of FXIIIa from platelets in response to ADP could in part be 
mediated by P2Y1 receptor. Alternatively, steps involved in sequential centrifugation of 
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PRP could have led to additional release of FXIIIa from platelets despite treatment with 
aspirin and clopidogrel.
Since FXIIIa has a role in facilitating platelet recruitment in flowing blood, future studies 
utilizing platelet deposition assays in contrast to aggregation based assays, could help further 
characterize the functional implications of FXIIIa release from platelets.
In conclusion, we demonstrate a substantial release of FXIIIa by platelets after stimulation 
with ADP in patients with coronary artery disease treated with clopidogrel and aspirin. 
Platelet derived FXIIIa may contribute to the generation of shear resistant, non-soluble 
plasma fibrin thrombus and in part explain variability in maximal clot strength phenotype 
observed in patients with coronary artery disease.
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Figure 1. 
Comparison of FXIIIa concentration in non-stimulated platelet poor plasma (PPP) and 
plasma supernatant (PSN) after platelet aggregation with ADP 5μM. Mean ± SEM (Panel A) 
and individual paired data (Panel B).
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Figure 2. 
Scatterplots of measures of thrombelastography and FXIIIa concentrations. PPP: platelet 
poor plasma. PSN: plasma supernatant. TEG-G: maximal clot strength. FXIII PSN: FXIIIa 
concentration in plasma supernatant after platelet aggregation with ADP 5μM. FXIIIa Δ 
Platelet = FXIII ADP PSN – FXIIIa PPP.
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Figure 3. 
Comparison of FXIIIa concentrations (Panel A) and ratio of platelet derived FXIIIa to 
platelet count (FXIIIa/platelet) (Panel B) between clopidogrel responders (PRU≤208) and 
clopidogrel non-responders (PRU>208). Panel C) FXIIIa concentrations according to 
quartiles of maximal plasma clot strength (TEG-G). Panel D) Quartiles of FXIIIa derived 
from platelets (FXIIIa Δ Platelet) and TEG-G. PRU: platelet reactivity units. PPP: Platelet 
poor plasma. PSN: FXIIIa concentration in plasma supernatant after platelet aggregation 
with ADP 5μM. Δ Platelet = FXIII ADP PSN – FXIIIa PPP.
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Table 1
Demographics and clinical variables of subjects. Values represent mean ± SD.
Clinical Variables Frequency (%)
Age (mean ± SD) 56 ± 10
Male Gender (%) 51/96 (63)
African American (%) 28/96 (29)
Diabetes mellitus(%) 34/96 (35)
Body Mass Index(kg/m2, mean ± SD) 32.4 ± 7
Prior percutaneous coronary intervention (%) 86/96 (90)
Coronary Artery Bypass Grafting (%) 15/96 (16)
Peripheral Vascular Disease (%) 19/96 (20)
Hypertension (%) 92/96 (96)
Hyperlipidemia (%) 96/96 (100)
Current smoking (%) 49/96 (51)
Beta-Blocker 93/96 (97)
Angiotensin converting enzyme-inhibitor 82/96 (85)
Calcium Channel Blocker 18/96 (19)
Statin 88/96 (92)
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Table 2
Platelet aggregation measured by light transmittance aggregometry (LTA) and VerifyNow P2Y12. 
Thrombelastography (TEG) measurements: TEG-R (time to fibrin formation), TEG-K (time of initial clot 
formation), TEG-angle (angle of initial clot formation), TEG-MA and TEG-G (maximal clot strength). MPA: 
Maximal platelet aggregation. Values represent mean ± SD.
Measure Mean ± SD
MPA LTA ADP 5μM (%) 32.2 ± 12
VerifyNow P2Y12 (PRU) 206 ± 77
TEG – R (min) 8.7 ± 2.3
TEG – K (min) 1.7 ± 1
TEG – Angle 66.3 ± 10
TEG – MA (mm) 36.8 ± 8
TEG – G (dyn/cm2) 3054 ± 1198
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